<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22053180</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>10</Issue><PubDate><Year>2011</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Dengue type 4 live-attenuated vaccine viruses passaged in vero cells affect genetic stability and dengue-induced hemorrhaging in mice.</ArticleTitle><Pagination><StartPage>e25800</StartPage><MedlinePgn>e25800</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e25800</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0025800</ELocationID><Abstract><AbstractText>Most live-attenuated tetravalent dengue virus vaccines in current clinical trials are produced from Vero cells. In a previous study we demonstrated that an infectious cDNA clone-derived dengue type 4 (DEN-4) virus retains higher genetic stability in MRC-5 cells than in Vero cells. For this study we investigated two DEN-4 viruses: the infectious cDNA clone-derived DEN-4 2A and its derived 3' NCR 30-nucleotide deletion mutant DEN-4 2A&#x394;30, a vaccine candidate. Mutations in the C-prM-E, NS2B-NS3, and NS4B-NS5 regions of the DEN genome were sequenced and compared following cell passages in Vero and MRC-5 cells. Our results indicate stronger genetic stability in both viruses following MRC-5 cell passages, leading to significantly lower RNA polymerase error rates when the DEN-4 virus is used for genome replication. Although no significant increases in virus titers were observed following cell passages, DEN-4 2A and DEN-4 2A&#x394;30 virus titers following Vero cell passages were 17-fold to 25-fold higher than titers following MRC-5 cell passages. Neurovirulence for DEN-4 2A and DEN-4 2A&#x394;30 viruses increased significantly following passages in Vero cells compared to passages in MRC-5 cells. In addition, more severe DEN-induced hemorrhaging in mice was noted following DEN-4 2A and DEN-4 2A&#x394;30 passages in Vero cells compared to passages in MRC-5 cells. Target mutagenesis performed on the DEN-4 2A infectious clone indicated that single point mutation of E-Q(438)H, E-V(463)L, NS2B-Q(78)H, and NS2B-A(113)T imperatively increased mouse hemorrhaging severity. The relationship between amino acid mutations acquired during Vero cell passage and enhanced DEN-induced hemorrhages in mice may be important for understanding DHF pathogenesis, as well as for the development of live-attenuated dengue vaccines. Taken together, the genetic stability, virus yield, and DEN-induced hemorrhaging all require further investigation in the context of live-attenuated DEN vaccine development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hsiang-Chi</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, Department of Life Science, National Tsing Hua University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yen</LastName><ForeName>Yu-Ting</ForeName><Initials>YT</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wen-Yu</ForeName><Initials>WY</Initials></Author><Author ValidYN="Y"><LastName>Wu-Hsieh</LastName><ForeName>Betty A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Suh-Chin</ForeName><Initials>SC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009711">Nucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000596" MajorTopicYN="N">Amino Acids</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005814" MajorTopicYN="N">Genes, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007121" MajorTopicYN="N">Immunocompetence</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009711" MajorTopicYN="N">Nucleotides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012692" MajorTopicYN="N">Serial Passage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019595" MajorTopicYN="N">Severe Dengue</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014774" MajorTopicYN="N">Virulence</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22053180</ArticleId><ArticleId IdType="pmc">PMC3203870</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0025800</ArticleId><ArticleId IdType="pii">PONE-D-11-09711</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lambrechts L, Scott TW, Gubler DJ. Consequences of the expanding global distribution of Aedes albopictus for dengue virus transmission. PLoS Negl Trop Dis. 2010;4:e646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2876112</ArticleId><ArticleId IdType="pubmed">20520794</ArticleId></ArticleIdList></Reference><Reference><Citation>Paranjape SM, Harris E. Control of Dengue Virus Translation and Replication. Curr Top Microbiol. 2010;338:15&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">19802575</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 2002;10:100&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">11827812</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubler DJ. The global emergence/resurgence of arboviral diseases as public health problems. Arch Med Res. 2002;33:330&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">12234522</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science. 1988;239:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">3277268</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigau-Perez JG, Clark GG, Gubler DJ, Reiter P, Sanders RJ, et al. Dengue and dengue haemorrhagic fever. Lancet. 1998;352:971&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pubmed">9752834</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster DP, Farrar J, Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect Dis. 2009;9:678&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pubmed">19850226</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB, Heinz FX, Barrett ADT, Roehrig JT. Dengue virus: molecular basis of cell entry and pathogenesis, 25&#x2013;27 June 2003, Vienna, Austria. Vaccine. 2005;23:849&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pubmed">15603884</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB. Dengue virus-mosquito interactions. Annu Rev Entomol. 2008;53:273&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">17803458</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine. 2000;18:44&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">10821973</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin AP, Whitehead SS. Dengue Vaccine Candidates in Development. Curr Top Microbiol. 2010;338:129&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">19802583</ArticleId></ArticleIdList></Reference><Reference><Citation>Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg. 2003;69:48&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">14740955</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J. 2004;23:99&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">14872173</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: Role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg. 2002;66:264&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">12139219</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol. 2007;5:518&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">17558424</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanesa-Thasan N, Edelman R, Tacket CO, WassermanSS, Vaughn DW, et al. Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am J Trop Med Hyg. 2003;69:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">14740951</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg. 2003;69:24&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">14740952</ArticleId></ArticleIdList></Reference><Reference><Citation>Aunins JG. Viral vaccine production in cell culture. In: Spier RE, editor. Encyclopedia of Cell Technology John Wiley &amp; Sons. 2000;2:1182&#x2013;1217.</Citation></Reference><Reference><Citation>Arroyo J, Guirakhoo F, Fenner S, Zhang ZX, Monath TP, et al. Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol. 2001;75:934&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC113989</ArticleId><ArticleId IdType="pubmed">11134306</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever Japanese encephalitis chimeric viruses: Construction and biological properties. J Virol. 1999;73:3095&#x2013;3101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC104070</ArticleId><ArticleId IdType="pubmed">10074160</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3&#x2032;-untranslated region. Am J Trop Med Hyg. 2001;65:405&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">11716091</ArticleId></ArticleIdList></Reference><Reference><Citation>Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol. 2001;75:7290&#x2013;7304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC114964</ArticleId><ArticleId IdType="pubmed">11462001</ArticleId></ArticleIdList></Reference><Reference><Citation>Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology. 2002;298:146&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">12093182</ArticleId></ArticleIdList></Reference><Reference><Citation>Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, et al. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol. 2004;78:4761&#x2013;4775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC387722</ArticleId><ArticleId IdType="pubmed">15078958</ArticleId></ArticleIdList></Reference><Reference><Citation>Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol. 2000;74:5477&#x2013;5485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC112032</ArticleId><ArticleId IdType="pubmed">10823852</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CYH, Butrapet S, Tsuchiya KR, Bhamarapravati N, Gubler DJ, et al. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol. 2003;77:11436&#x2013;11447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC229366</ArticleId><ArticleId IdType="pubmed">14557629</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinney RM, Butrapet S, Chang GJ, Tsuchiya KR, Roehrig JT, et al. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology. 1997;230:300&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">9143286</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CJ, Bray M, Men R, Cahour A, Chen W, et al. Evaluation of molecular strategies to develop a live dengue vaccine. Clin Diagn Virol. 1998;10:173&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">9741643</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CJ, Zhao BT, Hori H, Bray M. Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. Proc Natl Acad Sci USA. 1991;88:5139&#x2013;5143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC51827</ArticleId><ArticleId IdType="pubmed">2052593</ArticleId></ArticleIdList></Reference><Reference><Citation>Men R, Bray M, Clark D, Chanock RM, Lai CJ. Dengue type 4 virus mutants containing deletions in the 3&#x2032; noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol. 1996;70:3930&#x2013;3937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC190271</ArticleId><ArticleId IdType="pubmed">8648730</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaney JEJ, Johnson DH, Manipon GG, Firestone CY, Hanson CT, et al. Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology. 2002;300:125&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">12202213</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaney JE, Manipon GG, Firestone CY, Johnson DH, et al. Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells. Vaccine. 2003;21:4317&#x2013;4327.</Citation><ArticleIdList><ArticleId IdType="pubmed">14505914</ArticleId></ArticleIdList></Reference><Reference><Citation>Stinchcomb DT, Kinney RM, Huang CY, Wiggan O, Kalanidhi AP, et al. Development of dengue 2-PDK-53-based chimeric tetravalent dengue vaccines. 2007. 58 Third Asian Regional Dengue Research Network Meeting, Taipei, Taiwan.</Citation></Reference><Reference><Citation>Liu CC, Lee SC, Butler M, Wu SC. High genetic stability of dengue virus propagated in MRC-5 cells as compared to the virus propagated in vero cells. PLoS ONE. 2008;3:e1810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2265545</ArticleId><ArticleId IdType="pubmed">18350148</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JEJ, et al. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis. 2005;191:710&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pubmed">15688284</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HC, Hofman FM, Kung JT, Lin YD, Wu-Hsieh BA. Both virus and tumor necrosis factor alpha are critical for endothelium damage in a mouse model of dengue virus-induced hemorrhage. J Virol. 2007;81:5518&#x2013;5526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1900309</ArticleId><ArticleId IdType="pubmed">17360740</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu-Hsieh BA, Yen YT, Chen HC. Dengue hemorrhage in a mouse model. Ann N Y Acad Sci. 2009;1171(Suppl 1):E42&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">19751401</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugachev KV, Guirakhoo F, Ocran SW, Mitchell F, Parsons M, et al. High fidelity of yellow fever virus RNA polymerase. J Virol. 2004;78:1032&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC368746</ArticleId><ArticleId IdType="pubmed">14694136</ArticleId></ArticleIdList></Reference><Reference><Citation>Trent D. WHO working group on technical specifications for manufacture and evaluation of dengue vaccines, Geneva, Switzerland, 11&#x2013;12 May 2009. Vaccine. 2010 doi: 10.1016/j.vaccine.2010.10.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.10.043</ArticleId><ArticleId IdType="pubmed">21036129</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers TJ, Droll DA, Tang Y, Liang Y, Ganesh VK, et al. Yellow fever virus NS2B-NS3 protease: characterization of charged-to-alanine mutant and revertant viruses and analysis of polyprotein-cleavage activities. J Gen Virol. 2005;86:1403&#x2013;1413.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831952</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers TJ, Grakoui A, Rice CM. Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites. J Virol. 1991;65:6042&#x2013;6050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC250270</ArticleId><ArticleId IdType="pubmed">1833562</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandramouli S, Joseph JS, Daudenarde S, Gatchalian J, Cornillez-Ty C, et al. Serotype-specific structural differences in the protease-cofactor complexes of the dengue virus family. J Virol. 2010;84:3059&#x2013;3067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826037</ArticleId><ArticleId IdType="pubmed">20042502</ArticleId></ArticleIdList></Reference><Reference><Citation>Falgout B, Pethel M, Zhang YM, Lai CJ. Both Nonstructural Proteins Ns2b and Ns3 Are Required for the Proteolytic Processing of Dengue Virus Nonstructural Proteins. J Virol. 1991;65:2467&#x2013;2475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240601</ArticleId><ArticleId IdType="pubmed">2016768</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusof R, Clum S, Wetzel M, Murthy HMK, Padmanabhan R. Purified NS2B/NS3 Serine Protease of Dengue Virus Type 2 Exhibits Cofactor NS2B Dependence for Cleavage of Substrates with Dibasic Amino Acids in Vitro. J Biol Chem. 2000;275:9963&#x2013;9969.</Citation><ArticleIdList><ArticleId IdType="pubmed">10744671</ArticleId></ArticleIdList></Reference><Reference><Citation>Erbel P, Schiering N, D'Arcy A, Renatus M, Kroemer M, et al. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat Struct Mol Biol. 2006;13:372&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">16532006</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinworth RI, Fairlie DP, Leung DL, Young PR. Homology model of the dengue 2 virus NS3 protease: putative interactions with both substrate and NS2B cofactor. J Gen Virol. 1999;80:1167&#x2013;1177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10355763</ArticleId></ArticleIdList></Reference><Reference><Citation>Droll DA, Krishna Murthy HM, Chambers TJ. Yellow fever virus NS2B-NS3 protease: charge-to-alanine mutagenesis and deletion analysis define regions important for protease complex formation and function. Virology. 2000;275:335&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">10998334</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CYH, Butrapet S, Pierro DJ, Chang GJ, Hunt AR, et al. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol. 2000;74:3020&#x2013;3028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC111800</ArticleId><ArticleId IdType="pubmed">10708416</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>